Suppr超能文献

额外的肝外原发性恶性肿瘤对肝细胞癌患者预后的影响。

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma.

作者信息

Yeh Ming-Lun, Huang Ching-I, Huang Chung-Feng, Hsieh Ming-Yen, Lin Zu-Yau, Huang Jee-Fu, Dai Chia-Yen, Yu Ming-Lung, Chen Shinn-Cherng, Chuang Wan-Long

机构信息

Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

出版信息

PLoS One. 2017 Sep 28;12(9):e0184878. doi: 10.1371/journal.pone.0184878. eCollection 2017.

Abstract

BACKGROUND

The impact of additional extra-hepatic primary cancer (EHPC) on the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain.

METHODS

We retrospectively analyzed the cancer registration database from a tertiary hospital in Southern Taiwan. Patients who were diagnosed with HCC from 2008 to 2012 were enrolled. Overall survival (OS), HCC-specific survival and recurrence after curative therapy were analyzed and compared between the patients with and the patients without EHPC.

RESULTS

EHPC was found in 121/1506 (8.0%) patients. HCC patients with EHPC were older, more likely to be classified as Child-Pugh A, less likely to have viral hepatitis B or C, more likely to be single, had early stage HCC and received curative therapy for HCC. The OS did not significantly differ between the patients with and without EHPC(p = 0.061). However, significantly higher HCC-specific survival was observed in patients with EHPC (p<0.001), and a higher rate of non-HCC mortality was demonstrated in patients with EHPC (54.4% vs 9.3%). The subgroup analysis revealed better OS in patients with EHPC who were older than 65, had viral hepatitis B or C, had non-stage 1 HCC, had non-early stage BCLC and received non-curative therapy. Conversely, patients with HCC stage 1 who received curative therapy exhibited worse OS if they also had EHPC. The analysis of recurrence after curative therapy showed no difference between the two groups.

CONCLUSIONS

Our results implied that EHPC did not affect OS, but HCC-related survival was better in patients with EHPC. Based on these findings, the management of additional primary cancer is warranted.

摘要

背景

额外的肝外原发性癌(EHPC)对肝细胞癌(HCC)患者预后的影响仍不确定。

方法

我们回顾性分析了台湾南部一家三级医院的癌症登记数据库。纳入2008年至2012年诊断为HCC的患者。分析并比较了有EHPC和无EHPC患者的总生存期(OS)、HCC特异性生存期以及根治性治疗后的复发情况。

结果

1506例患者中有121例(8.0%)发现有EHPC。有EHPC的HCC患者年龄更大,更可能被归类为Child-Pugh A级,患乙型或丙型病毒性肝炎的可能性更小,更可能单身,HCC处于早期且接受了HCC的根治性治疗。有EHPC和无EHPC的患者OS无显著差异(p = 0.061)。然而,有EHPC的患者HCC特异性生存期显著更高(p<0.001),且有EHPC的患者非HCC死亡率更高(54.4%对9.3%)。亚组分析显示,年龄大于65岁、患有乙型或丙型病毒性肝炎、HCC非1期、BCLC非早期且接受非根治性治疗的有EHPC患者OS更好。相反,接受根治性治疗的1期HCC患者若同时有EHPC则OS更差。根治性治疗后复发情况分析显示两组无差异。

结论

我们的结果表明,EHPC不影响OS,但有EHPC的患者HCC相关生存期更好。基于这些发现,有必要对额外的原发性癌进行管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12aa/5619714/c1271f5c7a01/pone.0184878.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验